Detalles de la búsqueda
1.
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.
CA Cancer J Clin
; 73(5): 480-515, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36939293
2.
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?
CA Cancer J Clin
; 71(1): 34-46, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32997807
3.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256976
4.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 387(3): 217-226, 2022 07 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35857659
5.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35665782
6.
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Lancet Oncol
; 25(4): 474-487, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38547892
7.
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Lancet Oncol
; 25(3): 317-325, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38342115
8.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Lancet Oncol
; 25(2): e73-e83, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301705
9.
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Breast Cancer Res
; 26(1): 36, 2024 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38439079
10.
Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
Int J Cancer
; 154(4): 701-711, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37831416
11.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10411): 1423-1433, 2023 10 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37633306
12.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882206
13.
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
Breast Cancer Res Treat
; 203(2): 197-204, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37815684
14.
Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.
Breast Cancer Res Treat
; 204(3): 509-520, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194132
15.
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
Breast Cancer Res Treat
; 204(2): 249-259, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38123789
16.
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin
; 67(4): 290-303, 2017 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28294295
17.
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary.
Future Oncol
; 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38536033
18.
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Future Oncol
; 20(11): 635-651, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38270051
19.
Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study.
Future Oncol
; 2024 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517416
20.
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Future Oncol
; 20(1): 5-16, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37916267